Jefferies Global Healthcare Conference - BIOAGE LABS INC
Great. Welcome, everyone, to Jeffrey's 2026 Global Healthcare Conference in London. My name is Roger Song, Senior Analyst, Cover Semicarp Biotech in the U.S. It is my pleasure to have the FISA Chair with BioAge Labs, and then we have a CEO, Kristen Forney. Welcome, Kristen. Thanks, Roger, for having me. We're happy to be here. Awesome. All right. I would like you to get started by giving us the overview of the BioAGE, And honestly, what's missing by the investors? Why are you excited about that bio-aging story? Yeah, for sure. I mean, so in very broad strokes, we're a company focused on metabolic aging. We have a platform to find promising targets that's partnered preclinically with Novartis and Lilly. Our most advanced asset is an NLRP3 inhibitor with potential best-in-class features in Phase II for two different trials. We'll go into more detail on that later. And we're going to be back in the clinic with APJ soon as well. we're on track to file our IND for that program by the end of next year, and that is going to be open up another indication area, really back to obesity. And to your question, Roger, I'm assuming you mean NLRP3, right? Yeah, yeah. And I think there's been, you know, waning enthusiasm for that target, and the cause of that is, I think, pretty obvious. The Zeus trial, which was a huge disappointment. So as probably everyone is aware, the cardiovascular indication was a huge area of focus for NLRP3, given that it sits upstream of IL-6 and also IL-1, which showed such great efficacy in the CANTOS trial. But with IL-5 not working and the cost of those trials so large, the enthusiasm has waned. What we're forgetting, though, and to your point, I think, what are investors missing, is that IL-7 and IL-8 drugs are approved in excess of a billion-dollar products across multiple indications. So there's a lot of different opportunities to take an NLRP3 inhibitor, where, frankly, just the prospect of an oral medicine that does the same is already attractive. But there's the additive benefit that, you know, as in cardiovascular disease, most of these indications are not like single cytokine indications, right? There's a whole load of inflammatory cytokines that are relevant. There's benefits to going upstream to, you Know, a more causal target like NLLP3. related to that too you know i'll just mention this this briefly not to beat a dead horse right but we still really are excited about cardiovascular disease you know it's not something that we can do practically like what i what i've told a lot of people is like you know what if it were a 50 million dollar trial we would go and do it of course we would you know il1 still worked it showed great data there's a lot reason to believe but given where it is right now where the you know the state of the market is and the data, that's deprioritized for us. Yeah, that makes sense. I think you surprised most people on the street. You know, it is a risky binary cardiovascular outcome. People are questioning why CVLT should run this way and then why the POS is so low. That's another topic, but, you know, NRP3 is definitely the collateral damage to that and to the list. I think BioAge is quickly pivot to a new indication of thermology which makes a lot of sense just like you said earlier you have a lot on the biology side give us a little bit more color around NRP3 upstream inhibition why you think you can be better if not comparable if not better and then also on the safety side infection etc so why you thinks NRP is the right approach to target that indication. Yeah, for sure. So we're really excited about NLRP3 for inflammatory diseases of the retina. And we've been excited about this target in this space for a long time. We announced our ophthalmology strategy earlier this year. We had an R&D day to go through the rationale. And part of what makes it attractive is what you alluded to. So in diabetic macular edema specifically, and this is the first inflammatory retinal disease we're going to pursue, there is IL-6 drugs. Unlike in cardiovascular disease, they move the a provable endpoint. They've been shown to improve vision with Roche's drug, with Kodiak's drug which is really exciting and physicians are starting to get really excited about the inflammatory class. So here too you know IL-6 is not the only inflammatory cytokine that matters. You know IL1, IL18, VEGF is downstream of that as well. Pyreptosis is very much implicated in DME so we think there's a lot of benefits to going upstream. The clearest one though especially in the context of eye disease is that this is an oral drug, right? I mean, you know, these patients, an eye injection is a pretty serious intervention to get, right, so it's much more appealing to have an oral drag, and importantly, this lets us access a huge chunk of new patients that are not currently addressed, so if you talk to all the physicians right now, 30 to 40 percent of patients with DME, they're not treated yet because an eye injection is really invasive, So they'd really love to have, and they're excited by the prospect of an oral once a day that could show something like four letters of improvement. So that's like the most obvious place where this could play. We think there's potential to be superior to IL-6 as well in combination with VEGF. And, of course, there's all those patients that are refractory to VEJF, and the rationale there is very similar, right? Like if you're not responding to the VEBF, the doctor will take you off it because it's pretty, you know, invasive as a procedure, right. So we're really excited about that. we have great efficacy preclinically. We have the human validation. And a separate point, too, is that in DME specifically, the body is not just, you know, a convenient way to access the eye, right? This is happening in the context of diabetes, where there should be benefits to this mechanism as well. Physicians are excited about the systemic anti-inflammatory properties as well, which you're not going to do with an IL-6 drug. Yeah. Okay, great. You know, that's a rationale why you pick, you know, NRP3 co-work in the DME or broad-lay ophthalmology. Maybe just specifically talk about the BEG-102. So what are the special property compared to any other NRP? So far, I don't know any other NRP2 really targeting this ophthalmalogy. Seems the field is diversifying, right, so different indication, which makes sense because NRP1 can, very upstream and can target many different indication. And the BioAge is focused on the ophthalmelogy, which is great, and then a very important indication. So will you think that 102, the property can well suited for the ophthalmology? You mentioned some in the access to the brain. Yeah, this might be a unique feature of our molecule. We don't know, right? But so far we have the best brain penetration in the clinic with the KPUU and the CSF of 0.7. And that's likely related to its ability to penetrate the eye. The blood retina barrier and the blood brain barrier are very similar. We've seen preclinically that we get, you know, above IC90 levels in the retina across multiple species, including the primate, right, which is really exciting. And these other molecules might not get there. They might not be able to access this compartment. So this is a really important and unique feature of our molecule that we want to take advantage of, especially in ophthalmology. That said, though, even peripherally, we have best-in-class properties. So we announced our Phase I data back in April. We showed, you now, the best CRP reductions to date. Of course, that biomarker is now maybe in a little bit less focus. At the time, people cared more about CRP than IL-1, but we actually have best-in-class IL-2 inhibition as well. Other molecules targeting NLRP3 or NEX-7 have shown at most 90% inhibition of IL-3, and we go all the way to 98% in phase one. That's another important differentiator here, especially given that there are a number of indications where IL-4 drugs are approved. and we should be able to hit that with BG102. Got it. Okay. One specific question related to the PKPDA. How's the REN target coverage at your study dose? Yeah, we would anticipate it being above IC90 from the work we've done preclinically, as well as our human brain data, which is consistent with what we've seen preclinkly, where we have very high penetration into the brain. We will, as part of this phase two, be measuring levels in the eye, in the aqueous, as well als IL-6 target engagement. Okay. Great. All right. As you said, yeah, you're running phase two right now. So remind us, what is the key study design? And then more importantly, how you enroll those patients? What's the inclusion-exclusion criteria to improve or increase the likelihood of success here? Yeah. As a DME trial, this is not exotic. The one thing I would note is that it is three months in length. And if you go and you look at the IL-6 data from Roche and from others, What's really nice is that you actually see close to the maximal benefit after two to three months on drug that's then maintained over a longer period. So that's great. It means we can run a three-month study to see if our drug works. It's 180 patients altogether. Meant to answer some of these questions we were just discussing, like first of all, can this be really effective as a monotherapy? But also, is there additive benefit in it on top of a VEGF, which is where IL-6 has shown the most promise? So we have three different arms, 60 patients per arm, And we're powered to show a four-letter improvement either as a monotherapy or as the combination compared to a VEGF alone. And those are both, you know, exciting questions that we're going to come out of with the study. Got it. So far, how's the baseline look like? Because, you Know, you definitely have approved the drug. And then how do patients enroll that they are representative of the real world and then any bias and potential can impact the outcome? Yeah, no, these are very much representative patients. You know, like these studies are all run at similar sites. This trial is entirely in the United States, for example. Okay. Okay, got it. You mentioned four-letter improvement. You say both monotherapy and the combination. Which one is, you know, what's the power between those two? Because I think, you don't match F-ARM, you're not compared, they're a little bit higher. And then what's their power? Yeah, what we shared, and this is in our presentation, is that we have 90% power to answer either of those questions. Oh, okay, similar power. Yeah, very similar power, yeah. Okay, got it. And then so the answer you want to try to address is one is the add-on to the VEGF and the other one is a monotherapy. How's the use case going to look like and then how likely one or two or an RP3 at the order will become the first-line treatment? You know, we're thinking about, you know, initial adoption, and then the longer-term adoption. Yeah, I mean, you know, assuming we see equal efficacy in both cases, we think cracking that initial segment of patients who are currently not served by anything is the most exciting opportunity, but we really think there's different patient segments where the mechanism can be additive and valuable. Okay, got it. And so the study is independently powered to trial? It's a phase two. It's, you knows, stats really depends on you. And then would that stop plan sufficient to support a phase three? And then what's the next step after this? So that was one of the reasons we designed it this way. So, yes, there is the potential after this to go directly into a pivotal trial. And that's what we would love to do, of course. Yeah, contingent on the data that we see. Okay. And then it can be independent, right? So if you show benefit at the monotherapy. Yeah, that's going to directly inform exactly how we would design the pivotal trial because there's these different patient populations and different questions to discuss and address. Got it. And then how's the safety blinded or monitoring so far? And then what could be the potential risk, keep you up at night, say, okay, this is something I need to really think about it? Yeah, I mean, so far so good, right? The phase one data we released back in April was very clean, not much difference versus placebo. We're going to have three-month data, you know, including the same dose that we're using in the eye trial, reading out by the end of this year. So we're going to be sharing that broadly, but we think that this mechanism in our drug has the potential to be, you know, well-tolerated chronically, yeah. Got it. And then you mentioned the three- or four-letter kind of improvement over VEGF or monotherapy. That's considered to be clinically meaningful, we agree. That's, yeah, yeah on the other side, you have other benefits, right? So it's an oral drug, and then you don't need to inject your eyes. So what would be the bare minimum, you can say, because it's a power, but what if you come a little bit shy of this? And how you think about this profile will be sufficient for you to do a larger trial and then maybe convince the investor to give you the capital to run the phase three. Yeah, I mean, four letters is where we're powered. Maybe if it's even three letters, that would be exciting as an oral. But then you're kind of bumping into placebo effect, right? So you can't really go lower than that. Three to four. So that's the other. How about the mono therapy versus the combination therapy? To me, if a patient, they don't need to inject their eye at all, right? So that's probably pretty meaningful. Well, that's right. That's where that three letters came from, actually. Physicians saying that even a three-letter improvement, that would be very exciting for this patient segment that has not seen anything. Three letters is more for the mono-therapy. Four letters is much more for that combination. Yes, very close, of course, right, but sure. Got it. That's also what's been shown similarly with the IL-6s, right. So that's the magnitude of effect that's been seen previously with other anti-inflammatories. Got it. Okay. DME is just one of the ophthalmology franchise, and I believe you're thinking about GA as well. So how does the research give you the confidence you can expand broadly to other eye disease? Yeah. So we're excited about NLRP3 and inflammatory retina in general, right? So there's geographic atrophy where the science makes a lot of sense. There's, of course, also UME and MEZI, right, where Kodiak has shown some promising data where there's maybe even greater efficacy with an anti-inflammatory. So we're looking very carefully at both of those. But GA, to your point, it's really kind of uncorrelated as a disease, right? It's different mechanistically. So it will be nice to see the eye levels of the drug, but we think that there's a separate, very compelling rationale for the inflammasome in geographic atrophy. There's very nice genetic evidence, right. We've seen really great efficacy in our animal models. There's a small company, Inflammasome Therapeutics, with some really intriguing early data that you might have seen. Like several patients, you know, they keep on releasing data over the year, and it's been quite positive, where they have an inflammasome implant in an eye. So it's an inflamma-zone inhibitor that's an implant. So not competitive from a, you now, a treatment perspective, but de-risking. And they've shown very, you known, profound changes in the GA patients. So we're really excited to go into that indication, too. One of the reasons we went first for DME is really just because you can look in three months and see a nice signal, and GA is, of course, a longer trial, but that's a good one. Got it. Any other indication of potential beyond those two? Yeah. So, I mean, you know, this is a drug that acts not only in the eye, also in the brain, also on the periphery, right? So, as I mentioned, we have our QUEL-CV trial reading out at the end of this year. Now, this was a trial that we originally conceived to go right into a phase 3 MACE next year. as we discussed that we're no longer doing that, right? But what I do like to emphasize now is that that trial is much broader than a cardiovascular trial. The baseline characteristics there, these are, you know, obese patients with inflammation at baseline who are predisposed to, you know? MASH, diabetes, heart disease, all sorts of things. And we're looking at a really rich set of inflammatory and metabolic biomarkers in the blood, also with MRI. And importantly, we're looking at three different doses. So we're doing 30, 60, and 90 milligrams once a day. And the open question for us is that if you're looking at a peripheral indication, you know, is 90 any better than 60? Or are they the same in terms of the biomarker induction? So we'll walk out of that trial with a dose for any peripheral indication we take forward. And while I don't have a specific one to talk to you about today, we are going to be announcing one next year, a peripheral indication. Like, you know, as we've discussed at the beginning, there's a number of indications where IL-1s or IL-6s are approved, right? So we're going to select one of those and move forward with another trial and another indication where we can look at that approvable endpoint. So more on that next year. Got it. Okay. So that's a peripheral indication. That's beyond the ophthalmology we're talking about. Okay. and then that probably will be informed by this CV data and then those biomarkers when you report the data to us and then would you give us some hints okay this is a couple biomarker really good for certain disease and then obviously you're going to select or choose the one that makes most sense to you. Yeah I mean I think the most important thing for our next study is really going to be the dose. The biomarkeras we're partly expecting to see what we've already seen in the phase one. We'll be looking at a broader set. In terms of announcing the new indication, we just want to wait until we're closer to actually starting, to actually enrolling patients. Is it a competitive space? It's a competitive place. Yeah, that's right. Okay, and take a step back. We didn't talk about the market size. This is a, you have approved the drug, you have a pipeline coming, so probably new approval. How do you think about NRP3 will fit into this space? As you mentioned, it's an oral drug. If we can get to three to four letter and talk about DME for a moment. How about the market size you're thinking NRP3 can grab? Yeah, I don't want to make specific projections, right? But as we mentioned, something like 30% to 40% of DMA patients are not taking anything right now, right, so that's like a very clear, you know, opportunity to model. There's, of course, the refractory patients as well and the potential added benefit above the injections, but, like, that's sort of the clearest first value proposition. Got it. Yeah, we see that example, you know, for the oral drug, they basically expand the systemic kind of treatment population. Yes. Yeah, they will switch some of the injectable if you have some good profile and then add the oral drugs, but usually they will get a lot of... That's a good point, right? You can do by Jeff Sparing, too. Maybe you wait longer between shots, right, like there's other sort of extensions of the watch and wait population. That's right. Ophthalmology is not necessarily the, you know most active kind of drug development uh the path you know the area do you aware of any other oral targeted therapy for DME um not other ones that we're following closely most of these are injectables right and I think IL-6 is the the exciting one right now yeah and similarly in GA right there's not a whole lot beyond complement that's being explored most of the things in the clinical pipeline for DMEs are different VEGFs yeah got it okay makes sense um anything else so we should know about your world, your NLP3 before we have a couple minutes. I think we've covered most of it, right? There's a lot of promising indications and we'll have more to share on the indications shortly. Okay, and the data, Cloud CV data should be by the end of the year. That's the end the year, so that'll be coming soon, yeah. Good, we don't have many working weeks. No, we do not. Okay, got it. And then for the app, I'm really excited. You know I cover VCSpace very, very closely and broadly. We don't see many non-inquitin, non-MLN, let's say just non, it's novel mechanism. That's right, the field's open. Very, very open. If you look at the, I just came back from the obesity week and then people are talking about the novel. This year is very obvious, right? So you have fewer and fewer really still talk about the inquitin and obviously aminidate is oral and non-acting. That's how people understand. But novel is really taking the center stage. But the question is we don't have a good mechanism. That's correct. energy expenditure increased energy expenditure is one of the very clear phenotypical population we need to address and then maybe the good drug class apple is one a very good one so where are you now so into the corporate strategy and then also you have a compound is moving to the clinic quite well so how how how close that you know we should we'll be seeking yeah we're really excited to be back soon in the clinic with apolin so we're on track to hit our milestone of IND filing by end of year and at that point we'll roll out our clinical timelines as well as you know go into more details on the molecule itself the preclinical data all of that stuff and and as you mentioned right like the value proposition now especially for an oral is even more exciting than it was two years ago back when we had a Zellaprag right because in the meanwhile we've seen some of these oral incretin drugs get approved if anything they have weight loss below what we were hoping to see right and the potential for a complementary mechanism that you could have together you know in a single pill for example that enhanced the amount of weight loss preserved body composition it's really exciting right um and as you mentioned that the the field of alternative mechanisms is thin this is true in both the injectable and the oral space right i mean on the injectible space at least there's been magromab and inhibi we think those are interesting right and we're watching those but on the oralspace there's there's really not a lot right so i think there's still a lot of um value add there it would be very unique if you had you know the mechanism that could elevate an incretin an oral incretine to a best-in-class with the learning of the azaloprag right so this time i believe you're going to make this right and then how much how extensive right so preclinical tox package and then everything to give you the confidence you can you should move this into clinical yeah sure so as a refresher for people with azalaprag our original apj agonist that we in licensed from amgen and we did our phase two obesity study with Lilly, there were some liver enzymes elevations that emerged after a couple of months on drug, right? And the challenge there too was that that was not seen in, you know, in Amgen's preclinical work or in their phase one, right, so, so and what we were told basically, this is basically a hallmark of this sort of immune-mediated dilly, basically, which in the, in the you know we talked to a number of liver experts who basically told us this is always the structure's fault, you know, and so it was really important for us from the get-go to build something with zero structural similarity to azaloprag, and that's how we're approaching that, yeah, and in terms of the specific clinical experiments we're doing, we'll communicate those soon, but not today. Okay, got it, and then, as we said earlier, this is a novel mechanism, right, so the use case could be used as a monotherapy and the potential also as a small molecule. That's right. On the monotherapy side, what would be the strongest position that you think it could be, like an intolerant, refractory, or it can be just a gateway to the initial induction? Yeah, gateway or maintenance is really exciting, right? So we did publish preclinical data with Azeloprag, our previous molecule, showing that when you stick mice on a high-fat diet, they both gain less weight, and a higher proportion of that weight is muscle, so it's healthier weight gain on this mechanism so it could be an important part of a maintenance regime either alone or with a much lower better tolerated incretin dose so that's really exciting um but of course you know the easiest test and where you might see the biggest effect like pre-clinically this when you combine this mechanism with an incretine drug you double the amount of weight loss in an animal and it was that that sort of led to the design of our initial study with lily with our previous compound and that's that's an opportunity we're really excited about for this drug as well. But this was, you know, the origin story of this drug and this pathway for us was all around muscle preservation, right? And we actually showed in the clinic that this could preserve muscle in humans in a population of older people at bad rest. There's a number of different applications there, but the ones that we're most excited about are probably going to go after first are related to obesity. Okay, good. You know, this could be used as a combination and and very orthogonal to the current mechanism, how you, when design the drug and structurally, how much already in consideration, you know, feasibility of a combined, and then, by the way, we don't even know which compound you will combine. How are you gonna make sure this compound is suitable for future combination? Part of that is just size, right? So that was actually one of our original design goals, why we had a backup program in the first place, because we wanted to get the dose to something reasonable, right, But we think, you know, of course, it'll matter the characteristics of the other molecule, but we believe that it's amenable to that kind of combination approach. Potentially for, like, a fix-those combo? Yes. Okay, got it. All right, lastly, I think you're managing your capital pretty well, efficient, and then how's the cash runway? How much is funded for the current kind of pipeline plan? Yeah, so we're really funded through all the milestones we discussed today, including the additional unannounced peripheral indication. So we announced recently at our last quarterly update that we had just north of 350 million. So we are well capitalized to see through many different data readouts on NLRP3 and our APJ programs as well through phase one. Okay, and then did you say the peripheral new indication is also through proof of concept or how much? Yes, that's right. Got it. All right, I think that's it. Thank you so much, Kristen. Yeah, thank you, Roger. Awesome. Thank you. Thank you, everyone. Thank you.
- Company
- BIOAGE LABS INC
- Keywords
- BIOAGE LABS INC